The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Palonosetron (PALO) versus granisetron (GRA) in the triplet regimen with dexamethasone (DEX) and aprepitant (APR) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) with cisplatin (CDDP): A randomized, double-blind, phase III trial.
Hironobu Hashimoto
No relevant relationships to disclose
Takeharu Yamanaka
No relevant relationships to disclose
Yasuhiro Shimada
Honoraria - Taiho Pharmaceutical
Koji Arata
No relevant relationships to disclose
Reiko Matsui
No relevant relationships to disclose
Koichi Goto
No relevant relationships to disclose
Tomomi Takiguchi
No relevant relationships to disclose
Fumiyoshi Ohyanagi
No relevant relationships to disclose
Yuki Kogure
No relevant relationships to disclose
Naoyuki Nogami
No relevant relationships to disclose
Masahiko Nakao
No relevant relationships to disclose
Koji Takeda
No relevant relationships to disclose
Kanako Azuma
No relevant relationships to disclose
Seisuke Nagase
No relevant relationships to disclose
Toshinobu Hayashi
No relevant relationships to disclose
Kimiko Fujiwara
No relevant relationships to disclose
Toshikazu Shimada
No relevant relationships to disclose
Nobuhiko Seki
No relevant relationships to disclose
Kenichi Suzuki
No relevant relationships to disclose
Nobuyuki Yamamoto
No relevant relationships to disclose